Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Boehringer Ingelheim
McKinsey
AstraZeneca
McKesson

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR PIPERACILLIN AND TAZOBACTAM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Piperacillin And Tazobactam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003805 ↗ Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed European Organisation for Research and Treatment of Cancer - EORTC Phase 3 1997-11-01 RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00044746 ↗ Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2000-10-01 Phase IV Open-Label Foot Infection Study is being conducted to generate comparative Efficacy and Safety data in Diabetic Inpatients.
NCT00044759 ↗ Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 1969-12-31 To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
NCT00167999 ↗ Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units Completed Wyeth is now a wholly owned subsidiary of Pfizer 2005-02-01 To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Piperacillin And Tazobactam

Condition Name

Condition Name for Piperacillin And Tazobactam
Intervention Trials
Pneumonia 4
Enterobacteriaceae Infections 4
Infection 4
Bacteremia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Piperacillin And Tazobactam
Intervention Trials
Infections 24
Infection 23
Communicable Diseases 17
Pneumonia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Piperacillin And Tazobactam

Trials by Country

Trials by Country for Piperacillin And Tazobactam
Location Trials
United States 120
China 23
Italy 16
Germany 15
France 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Piperacillin And Tazobactam
Location Trials
Texas 8
Florida 8
California 7
Missouri 6
Ohio 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Piperacillin And Tazobactam

Clinical Trial Phase

Clinical Trial Phase for Piperacillin And Tazobactam
Clinical Trial Phase Trials
Phase 4 27
Phase 3 22
Phase 2/Phase 3 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Piperacillin And Tazobactam
Clinical Trial Phase Trials
Completed 43
Unknown status 11
Terminated 10
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Piperacillin And Tazobactam

Sponsor Name

Sponsor Name for Piperacillin And Tazobactam
Sponsor Trials
Merck Sharp & Dohme Corp. 9
Wyeth is now a wholly owned subsidiary of Pfizer 8
M.D. Anderson Cancer Center 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Piperacillin And Tazobactam
Sponsor Trials
Other 153
Industry 43
U.S. Fed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Merck
Medtronic
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.